Emerging treatment for congenital adrenal hyperplasia

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Purpose of reviewAlthough the basic treatment of congenital adrenal hyperplasia (CAH) is well established, there are active clinical research projects to more closely mimic the normal diurnal rhythm of cortisol secretion and to reduce total glucocorticoid doses to minimize adverse metabolic effects.Recent findingsWe review clinical studies on CAH treatment published in the last 18-months or currently underway according to ClinicalTrials.gov listings. These can be grouped into several broad themes: alternative dosing forms of hydrocortisone with altered pharmacokinetics or easier dose titration; corticotropin-releasing hormone receptor antagonists that reduce corticotropin (ACTH) secretion and thereby reduce adrenal androgen secretion; androgen biosynthesis inhibitors; a first clinical trial of a gene therapy vector.SummaryAlternative dosing forms of hydrocortisone are, or will shortly be, marketed, but cost may be a barrier to utilization, at least in the US market. Trials of corticotropin releasing hormone receptor antagonists and androgen biosynthesis inhibitors are currently underway. The author believes that trials of gene therapy for CAH are premature.

Original languageEnglish (US)
Pages (from-to)271-276
Number of pages6
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Issue number3
StatePublished - Jun 1 2022


  • ACTH
  • androgens
  • gene therapy
  • glucocorticoid

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics


Dive into the research topics of 'Emerging treatment for congenital adrenal hyperplasia'. Together they form a unique fingerprint.

Cite this